SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Has Consensus Target Price of $10.00

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have received an average rating of “Hold” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.00.

A number of analysts have recently commented on the company. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, October 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st.

Insider Buying and Selling at SOPHiA GENETICS

In other news, Chairman Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $326,598.36. Following the transaction, the chairman owned 3,395,650 shares in the company, valued at approximately $27,606,634.50. The trade was a 1.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 17,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the sale, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 250,662 shares of company stock worth $1,942,499. 4.88% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Sowell Financial Services LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at about $2,865,000. Maven Securities LTD bought a new position in shares of SOPHiA GENETICS during the second quarter worth about $866,000. AXQ Capital LP bought a new position in shares of SOPHiA GENETICS during the second quarter worth about $119,000. AWM Investment Company Inc. acquired a new position in shares of SOPHiA GENETICS in the second quarter worth approximately $9,809,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS in the second quarter worth approximately $567,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Stock Down 4.3%

Shares of SOPH opened at $7.63 on Friday. SOPHiA GENETICS has a 52 week low of $3.83 and a 52 week high of $8.98. The stock has a market capitalization of $640.12 million, a price-to-earnings ratio of -6.63 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The stock has a fifty day moving average of $7.87 and a 200-day moving average of $5.95.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. As a group, sell-side analysts anticipate that SOPHiA GENETICS will post -0.77 earnings per share for the current fiscal year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.